Market cap
$955 Mln
Revenue (TTM)
$183 Mln
P/E Ratio
24.1
P/B Ratio
5.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$40 Mln
-
ROE
0.3 %
-
ROCE
-- %
-
Industry P/E
45.24
-
EV/EBITDA
14.9
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$0.2
-
Face value
--
-
Shares outstanding
170,852,000
10 Years Aggregate
CFO
$-88.26 Mln
EBITDA
$-34.39 Mln
Net Profit
$-34.88 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Antares Pharma (ATRS)
| 56.6 | 0.4 | 65.9 | 37.0 | 25.3 | 17.2 | 6.7 |
|
BSE Sensex*
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Antares Pharma (ATRS)
| -10.5 | -15.1 | 72.8 | 36.5 | -14.6 | 92.6 | -52.9 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Antares Pharma (ATRS)
|
5.6 | 955.1 | 183.5 | 42.5 | 31.0 | 26.8 | 24.1 | 5.4 |
| 24.2 | 225.5 | 126.5 | -1.5 | -1.1 | -2.6 | -- | 2.4 |
Shareholding Pattern
View DetailsAbout Antares Pharma (ATRS)
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and... commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a Read more
-
CEO, Pres & Director
Mr. Robert F. Apple
-
CEO, Pres & Director
Mr. Robert F. Apple
-
Headquarters
Ewing, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Antares Pharma (ATRS)
What is the current share price of Antares Pharma Inc (ATRS) Today?
The share price of Antares Pharma Inc (ATRS) is $5.59 (NASDAQ) as of 24-May-2022 09:30 EDT. Antares Pharma Inc (ATRS) has given a return of 25.32% in the last 3 years.
What is the current PB & PE ratio of Antares Pharma Inc (ATRS)?
The P/E ratio of Antares Pharma Inc (ATRS) is 24.09 times as on 24-May-2022, a 47 discount to its peers’ median range of 45.24 times.
The P/B ratio of Antares Pharma Inc (ATRS) is 5.43 times as on 24-May-2022, a 85 premium to its peers’ median range of 2.93 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
13.50
|
3.55
|
|
2020
|
12.07
|
5.69
|
|
2019
|
-377.95
|
14.06
|
|
2018
|
-65.55
|
10.95
|
|
2017
|
-18.54
|
9.25
|
What is the 52 Week High and Low of Antares Pharma Inc (ATRS)?
The 52-week high and low of Antares Pharma Inc (ATRS) are Rs -- and Rs -- as of 10-May-2026.
What is the market cap of Antares Pharma Inc (ATRS)?
Antares Pharma Inc (ATRS) has a market capitalisation of $ 955 Mln as on 24-May-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Antares Pharma Inc (ATRS)?
Before investing in Antares Pharma Inc (ATRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.